A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2

Name: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2
Creator: Vivli
Published: 2025-05-01 01:02:10
License: 暂无描述

DataCite Commons2025-05-01 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00010897/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

Primary Objectives:Cohort A:• To evaluate the efficacy of REGN10933+REGN10987 compared to placebo in preventing symptomatic SARS-CoV-2 infection (broad-term) confirmed by RT-qPCRCohort A and Cohort A1:• To evaluate the safety and tolerability of REGN10933+REGN10987 following subcutaneous (SC) administration compared to placeboCohort B • To evaluate the efficacy of REGN10933+REGN10987 compared to placebo in preventing COVID-19 symptoms (broad-term)Cohort B and Cohort B1• To evaluate the safety and tolerability of REGN10933+REGN10987 following SC administration compared to placebo

提供机构：

Vivli

创建时间：

2024-12-12